Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

ClinicalTrials.gov ID: NCT01867125

Public ClinicalTrials.gov record NCT01867125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.

Study identification

NCT ID
NCT01867125
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
1,081 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 24, 2013
Primary completion
Dec 27, 2016
Completion
Dec 27, 2016
Last update posted
Jul 16, 2026

2013 – 2016

United States locations

U.S. sites
53
U.S. states
24
U.S. cities
52
Facility City State ZIP Site status
Alabama Clinical Research Associates Pell City Alabama 35128
Desert Sun Clinical Research LLC Tucson Arizona 85710
Allianz Medical and Research Center Fountain Valley California 92708
Allergy & Asthma Medical Group & Research Center, Pc Long Beach California 90808
Allergy Medical Clinic Los Angeles California 90025
CA Allergy & Asthma Med Grp Los Angeles California 90025
North Bay Clinical Trials Napa California 94558
Choc Psf, Amc Orange California 92868
Advances in Medicine Rancho Mirage California 92270
Allergy Assoc Medical Group San Diego California 92108
Bensch Research Associates Stockton California 95207
IMMUNOe Research Centers Centennial Colorado 80112
Waterbury Pulmonary Associates Waterbury Connecticut 06708
St. Francis Sleep; Allergy & Lung Institute Clearwater Florida 33765
Suncoast Research Group LLC Miami Florida 33135
Emerald Coast Research Associates Panama City Florida 32405
Allergy & Asthma Diagnostic; Treatment Center Tallahassee Florida 32308
Florida Pulmonary Research Institute, LLC Winter Park Florida 32789
Atlanta Allergy & Asthma Clini Woodstock Georgia 30188
Northeast Medical Research Associates, Inc North Dartmouth Massachusetts 02747
Midwest Clinical Research LLC St Louis Missouri 63141
Montana Medical Research LLC Missoula Montana 59808
Heartland Clinical Research Inc. Omaha Nebraska 68134
Asthma & Allergy Center, P.C. Papillion Nebraska 68046
Allergy & Asthma Associates Las Vegas Nevada 89104
Allergy & Asthma Research of Nj, Inc Mount Laurel New Jersey 08054
Atlantic Research Center, LLC Ocean City New Jersey 07712
Princeton Center For Clinical Research Skillman New Jersey 08558
Montefiore Medical Center The Bronx New York 10461
Allergy & Asthma Center of NC High Point North Carolina 27262
PMG Research of Wilmington Wilmington North Carolina 28401
Asthma & Allergy Center Toledo Ohio 43617
Cor Clinical Research Oklahoma City Oklahoma 73103
Allergy & Asthma Research Grp Eugene Oregon 97401-7721
Clinical Research Inst. of Southern Oregon, Pc Medford Oregon 97504
Allergy Associates Research Center LLC - CRN Portland Oregon 97202
Asthma Allergy Pulm Associates Philadelphia Pennsylvania 19107
Grand View Hospital; Clinical Research Department Sellersville Pennsylvania 18960
Asthma Allergy Phys of RI Lincoln Rhode Island 02865
ADAC Research PA Greenville South Carolina 29607
Spartanburg Medical Research Spartanburg South Carolina 29303
Tekton Research Inc Austin Texas 78745
TTS Research Boerne Texas 78006
Pharmaceutical Research & Consulting, Inc. Dallas Texas 75231
Pioneer Research Solutions Houston Texas 077099
Metroplex Pulmonology & Sleep Center McKinney Texas 75069
Quality Assurance Research Ctr San Antonio Texas 78205
O & O Alpan, LLC Fairfax Virginia 22030
Manassas Clinical Research Center Manassas Virginia 20110
Clinical Research Partners, LLC Richmond Virginia 23220
Bellingham Asthma, Allergy & Immunology Bellingham Washington 98225
ASTHMA, Inc Seattle Washington 98105
Premier Clinical Research Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01867125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01867125 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →